UNSPSC 51322202: Dalvastatin

This classification denotes an anti-lipidemic agent with the molecular formula C24H31FO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZWE0X0IG9D, chemically known as 2h-pyran-2-one, tetrahydro-6-(2-(2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethyl-1-cyclohexen-1-yl)ethenyl)-4-hydroxy-, (4r-(4-alpha,6-beta(e)))- but generally known as dalvastatin, which bears US NIH Compound Identifier 6436001. European Medicines Agency schedules Dalvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06894MIG.

UNSPSC 51322202 Dalvastatin is a Commodity code under which state and local governments procure specific branded and generic pharmaceutical products for emergency medical services, health agencies, and cooperative purchasing alliances. Recent solicitations show that buying under this code spans individual medications for first-responder use, generic multi-source pharmaceuticals distributed through cooperative purchasing vehicles, and exploratory market research into direct-to-manufacturer pharmacy programs. The issuing bodies include city fire departments (Tampa Fire Rescue via the City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participating jurisdictions). Scope centers on supply of specific drug line items with strict expiration-date and shelf-life requirements, compliance with FDA and cGMP standards, and delivery via authorized wholesale distributors or direct-to-order fulfillment.

Geographic activity spans Florida, Texas, Minnesota, Oregon, and other states participating in MMCAP. Representative recent opportunities include the City of Tampa's sealed-bid IFB (26P00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000 and a one-year term plus renewal options; MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, administered by Minnesota Department of Administration with a two-year initial term and optional extensions through June 30, 2028; and the Texas HHS Commission's RFI (HHS0017013) posted April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities before issuing a formal RFP. The Tampa solicitation includes a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation not to exceed $10,000, WCAG 2.2 Level AA accessibility documentation, and OSHA-compliant Safety Data Sheets. MMCAP vendors must maintain $5 million commercial general liability coverage, carry $2 million network security and privacy liability, and accept 3 percent administrative fees plus performance penalties of $200–$1,500 per violation.